Alphabit Fund Deploys Initial Investment into Stratis Protocol and Initiates Coverage
Blockchain as a Solution (BaaS) service provider Stratis makes decentralized adoption easier for any firm with its innovative products designed to fit seamlessly with legacy operations, by allowing companies access to the Stratis blockchain via the widely-used C# programming language. The platform allows seamless running of smart contracts, multiple sidechains, and houses a full-scale ICO platform.
Alphabit, a USD 1 billion AUM fund and one of the world’s first regulated digital asset investment funds focused on delivering turn-key solutions and assisting projects with end-to-end partnerships, enters into this venture to rapidly scale Stratis’ development and help deploy cutting edge products that allow mainstream organizations to use blockchain in their day to day operations. The significant commitment by Alphabit is a testament to the groundbreaking approach of Stratis’ offerings.
CEO of Alphabit Liam Robertson commented on the partnership: “Stratis Protocol, after analysis, fits neatly into our investment thesis and we believe the potential for growth for Stratis to be exponential. We are delighted to welcome Stratis into our portfolio and look forward to supporting them over the coming months and years.”
Stratis CEO Chris Trew said the following: “We are thrilled to partner with Alphabit, one of the world’s first regulated digital asset investment funds. Alphabits initial injection, in conjunction with their further investment commitment, will unquestionably assist in accelerating the adoption of Stratis Technologies, while cementing Stratis as the go-to platform for Microsoft .NET Blockchain development.”
With the expertise and backing of Alphabit, Stratis will be empowered to develop ever-better solutions for the b2b market. Coupled with their C# support, Stratis’ solutions will increase the onboarding of blockchain solutions in the global market.
About Stratis Stratis offers unprecedented levels of security, reliability and performance through leveraging blockchain. The first of its kind, the platform’s native C# ecosystem enables firms all over the world use their existing IT infrastructure and tools to adopt the technology by providing access to the Stratis blockchain’s features, in a language which is familiar to the everyday developer.
o Stratis Identity: A decentralized KYC and AML check to make it easier for businesses to verify client identities and comply with regulations. o Supply Trust: A turnkey solution for supply chain management, providing full visibility in a trustless and decentralized environment. o STO Platform: Regulation-compliant digital securities for businesses launching STO’s o Stratis Smart Contracts: Secure and auditable digital contracts that are developed in the industry-standard Microsoft C# language, fit for the DeFi age.
About Alphabit Alphabit specializes in investments in blockchain and distributed ledger technology projects. They offer a wide range of advisory services and act as the Investment Advisor to the Alphabit Fund; one of the world’s first regulated digital asset investment funds.
Their goal is to share their expertise with promising projects and advance the cryptocurrency movement as a whole, and to date, Alphabit has successfully brought to market projects like Metal Pay, The Sun Exchange, and Suterusu.
To find out more about how Stratis is bringing the next generation of blockchain to businesses, visit www.stratisplatform.com, or to see how Alphabit is empowering Blockchain businesses to reach new heights, visit www.alphabit.fund.
Pacific Green Technologies, Inc. (OTCQB:PGTK)) announces the appointment of Peter Rossbach as Non-Executive and Independent Director, effective February 1st, 2021.
Peter Rossbach has worked in the renewable power sector since 1985 starting with Standard & Poor rating renewable projects bonds in California.
Peter moved to Catalyst Energy, a developer of hydro and cogeneration projects before becoming VP of Project Finance for Mitsui Bank, specializing in structured debt for US based wind and cogeneration projects.
Peter has made dozens of investments in hydro, wind and solar projects in over twelve countries creating a portfolio of in excess of 1GW. Currently Peter serves as Senior Advisor and sits on the investment committee for a number of Impax’s private equity funds and is an Independent Director of UGE International Ltd, a TSX-listed PV solar company.
Peter has a degree in Government from Harvard College and a Masters’ degree in Public Policy from Harvard’s Kennedy School of Government.
Scott Poulter, PGTK’s Chief Executive commented: “Peter’s vast international experience and knowledge of the industry, along with his investment background, brings great strength to our business. His input will be hugely significant as we develop Pacific Green, into an industry leading renewable technology group globally.”
About Pacific Green Technologies, Inc. Pacific Green Technologies Inc. is focused on addressing the world’s need for cleaner and more sustainable energy. The Company offers BESS and Concentrated Solar Power (CSP) energy solutions to complement its marine environmental technologies and emissions control divisions. For more information, visit PGTK’s website: www.pacificgreentechnologies.com
Notice Regarding Forward-Looking Statements: This news release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the ongoing effects of the pandemic on delays and orders regarding Pacific Green’s technologies, potential business developments around the world and future interest in our green technologies.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, general economic and political conditions, and the ongoing impact of the pandemic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact: Scott Poulter, Chairman & CEO Pacific Green Technologies T: +1 (302) 601-4659
Tiger Brokers introduced two new services on their online trading platform – Daily Leveraged Certificates (DLCs) and selected US-listed over the counter (OTC) stocks
Tiger Brokers currently offers multi-currency trading such as USD, CNH, HKD, SGD, NZD and AUD – New York Stock Exchange (NYSE), NASDAQ, Shanghai/Shenzhen-Hong Kong Stock Connect, the Hong Kong Stock Exchange (HKEX), the Singapore Exchange (SGX), and Australian Securities Exchange (ASX)
Xiaomi-backed online trading platform Tiger Brokers Singapore today announced the launch of two new services on their platform – Daily Leveraged Certificates (DLCs), and US-listed over the counter (OTC) stocks, designed to help seasoned investors looking for a full suite of investment options to diversify their portfolios. These services allow Singapore-based users of the Tiger Trade platform look for short-term trades and selected US-listed over the counter (OTC) stocks where securities are traded for companies not listed on the main exchanges in the US, such as LVMH-MOET Hennessy Louis Vuitton (LVMHF), Softbank Group (SFTBY) and Bitcoin investment trust (GBTC).
The US OTC stocks service is now available on Tiger Brokers’ platform, and DLC by the end of February.
Eng Thiam Choon, CEO of Tiger Brokers shared, “We want to be a one-stop solution for our investors as we embrace more and more investment alternatives on our Tiger Trade platform. We have been seeing an increase of requests from our users to add DLCs and OTC services, especially in Q4 last year due to investors’ growing demands for differential investment instruments. It is important that we have a diversified list of product offerings to provide investors more opportunities and options when it comes to online trading.”
The new services add on to the investment products available to Tiger Trade users, beyond the six global exchanges – New York Stock Exchange (NYSE), NASDAQ, Shanghai/Shenzhen-Hong Kong Stock Connect, Hong Kong Stock Exchange (HKEX), Singapore Exchange (SGX), and Australian Securities Exchange (ASX). Other services include Tiger Brokers’ new product – Fund Mall, a one-stop-shop for investing in global mutual funds that allows investors access to more than 100 renowned funds, Equities, Exchange-Traded Funds (ETFs), Futures, Stock Options, Warrants, and Callable Bull/Bear Contracts (CBBCs).
Tiger Brokers recently also announced four new strategic partnerships that will strengthen the online trading platform by providing up to date financial information. The four new partners are – financial technology provider, Iress, one of the largest and most active online trading communities, TradingView, Global financial market data and infrastructure provider, Refinitiv; and Asia’s leading Financial Group, DBS for their Direct Debit Authentication fast deposit function that allows instant transfer for DBS clients on top of the current FAST transfer options available to Singapore banks and telegraphic transfer. Trade settlements can be done in various currencies on the trading app – USD, CNH, HKD, SGD, NZD and AUD, reducing extra charges incurred by currency fluctuations when trading on the various exchange platforms. Tiger Brokers looks to add more variations of currencies on their platform, further expanding the trading options for investors.
“Tiger Brokers aims to continue adding more products to the platform while strengthening its technology to empower a new generation of investors, enabling them to make judiciously executed trade regardless of market conditions,” added Thiam Choon.
Tiger Brokers is backed by US-based brokerage Interactive Brokers, Chinese tech giant Xiaomi and Wall Street investment guru Jim Rogers. The online trading platform currently has over 1 million customers worldwide, with a total trading volume of more than US$62.8 billion as of Q3 2020.
About Tiger Brokers (Singapore) Pte Ltd. Tiger Brokers Singapore Pte Ltd (Tiger Brokers Singapore) is a brokerage firm operating with a Capital Markets Services (CMS) Licence from the Monetary Authority of Singapore (MAS). Its trading platform, Tiger Trade, offers complimentary real-time stock quotes, dedicated multilingual customer service during trading hours and 24/7 finance news updates. The company launched the mobile version of Tiger Trade in February 2020 – accessible on Google Play Store and the Apple App Store – offering mobile-savvy generation of retail investors similar trading opportunities as their online users, such as Equities, Exchange-Traded Funds (ETFs), Futures, Stock Options, Warrants, and Callable Bull/Bear Contracts (CBBCs) on their mobile phones. Both online and mobile app allow users to invest across multiple asset classes traded on the Australian, US, Hong Kong, China and Singapore stock markets such as the New York Stock Exchange (NYSE), NASDAQ, Shanghai/Shenzhen-Hong Kong Stock Connect, the Hong Kong Stock Exchange (HKEX), the Singapore Exchange (SGX) and the Australian Securities Exchange (ASX).
Tiger Brokers Singapore is the Singapore entity of UP Fintech Holding Limited, known as “Tiger Brokers” in Asia, a leading online brokerage firm focusing on global investors. Founded in 2014, Tiger Brokers became #1 in the U.S. equity trading by volume among trading platforms catered to Global Chinese investors in less than two years. Tiger Brokers was awarded “2017 Fintech 250” by CB Insights and shortlisted for “China Leading Fintech 50” for two years in a row by KPMG China. The company was listed on NASDAQ under “TIGR” in 2019 and has offices in China, United States, Australia, New Zealand and Singapore. Tiger Brokers has over 1 million customers worldwide currently, with a total trading volume of more than US$62.8 billion in Q3 2020. The company is backed by well-known investors such as Xiaomi, as well as investment guru Jim Rogers. For more information, please visit https://www.tigerbrokers.com.sg.
For media enquiries, please contact: PRecious Communications for Tiger Brokers (Singapore) Email: Tiger@preciouscomms.com
This article has not been reviewed by the Monetary Authority of Singapore. Any views shared with Prospective Clients (“Prospects”) are suggestive in nature and on a sample basis only. This may also be predicated on assumptions that are made by Tiger Brokers (Singapore) Pte Ltd about the Prospects’ investment objectives and risk profile. Our suggestive and sample views extended to Prospects are not to be considered as recommendations made by the Company. Suggestions provided are also based on information that may be shared by the Prospects, the accuracy and comprehensiveness of which Tiger Brokers in not in a position to verify.
Tiger Brokers (Singapore) Pte Ltd (herein “Tiger Brokers”) may, to the extent permitted by law, participate or invest in other transactions with the issuer of the products referred to herein, perform services or solicit business from such issuers, and/or have a position or effect transactions in the securities or options thereof. The information herein is for recipient’s information only and not an offer to sell or a solicitation to buy. Any date or price information is indicative only and may be changed without prior notice. All opinions expressed and facts referred to herein are subject to change without notice. The information herein was obtained and derived from sources that we believe are reliable, but while reasonable care has been taken to ensure that stated facts are accurate and opinions are fair and reasonable, Tiger Brokers does not represent that it is accurate or complete and it should not be relied upon as such. The information expressed herein is current and does not constitute an offer, recommendation or solicitation, nor does it constitute any prediction of likely future stock performance. Investment involves risk. The price of investment instruments can and do fluctuate, and any individual instrument may experience upward or downward movements, and under certain circumstances may even become valueless. Past performance is not a guarantee of future results. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any person or affiliated companies. Before making an investment decision, you should speak to a financial adviser to consider whether this information is appropriate to your needs, objectives and circumstances. Tiger Brokers assumes no fiduciary responsibility or liability for any consequences financial or otherwise arising from trading in securities if opinions and information in this document may be relied upon.
Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has been selected(1) by Japan’s Ministry of Health, Labour and Welfare (MHLW) to implement the Japan-Russia Medical Cooperation Promotion Project in the field of endoscopy for the fiscal year ending March, 2021. Under the project, Olympus will promulgate gastrointestinal endoscopic/laparoscopic techniques in support of a five-year oncology plan launched by the Russian government in 2019.(2)
As part of the project, Olympus will facilitate online training programs for gastrointestinal endoscopic/laparoscopic techniques taught by Japanese oncology specialists for Russian endoscopists and oncologists. The bilateral project is being carried out in cooperation with Russia’s two premier cancer centers, the N. N. Blokhin Cancer Research Center and the P. Hertsen Moscow Oncology Research Institute branch of the Russian National Medical Research Radiological Centre (NMRRC) as well as Asian Medical Education and Training Support (AMETS).(3) As part of the project’s initiatives, Olympus commits to disseminate Japan’s world-leading technologies for early diagnosis and treatment in Russia, contributing to the improvement of oncology treatment and research in the region.
Objectives of the MHLW’s Japan-Russia Medical Cooperation Promotion Project in the Field of Endoscopy (April 2020 – March 2021):
1. To help advance the Russian government’s oncology plan by implementing cancer educational activities for facilities and doctors specializing in that branch of medicine. These activities will take place primarily at Russia’s two premier cancer centers, the N. N. Blokhin Cancer Research Center and the P. Hertsen Moscow Oncology Research Institute within the NMRRC.
2. To provide opportunities for training and knowledge sharing on the latest medical technologies by Japanese physicians, contributing to the improvement of gastrointestinal cancer measures, from diagnosis to treatment, particularly for colorectal cancer.
Program activities were unveiled at the Japan-Russia Symposium on Colorectal Cancer Management and at the Signing Ceremony of the Memorandum of Cooperation among AMETS and the two Russian cancer centers, which were held on January 19. The signing ceremony was attended by Japanese and Russian government officials, including Mr. Sergey Muraviev, Director-General, International Cooperation and Public Relations Bureau, Ministry of Health of the Russian Federation, Dr. Teiji Takei, MHLW Assistant Minister for Global Health and Welfare, and Mr. Takeshi Matsunaga, Embassy of Japan in Russia. In addition, 1167 healthcare professionals from all over Russia attended the symposium virtually.
Supported by the MHLW since 2017, Olympus has provided its endoscopic systems for the Endoscopic Training Center at Pirogov Russian National Research Medical University, in addition to supporting training activities with Japanese physicians serving as instructors. The Japan-Russia Medical Cooperation Promotion Project is one of such initiatives by Olympus that MHLW has supported. Moving forward, Olympus will continue to assist with the training of Russian endoscopists, aiming to spread the application of endoscopic diagnosis, treatment and surgery.
(1) Selection was made in June, 2020 (2) Preventive program centered around cancers in the Russian government’s national “Healthcare project” that aims to reform its healthcare system. The program, which is promoted by the directors from the two major cancer centers mentioned above, targets an early cancer detection rate of 63% or greater, 5-year survival rate of 60% or greater, and a mortality rate of 17.3% or less. Colorectal cancer is currently the second most prevalent type of cancer in Russia. (3) A general incorporated institution whose mission is to help spread access to Japan’s world-class endoscopy and other medical technologies throughout Asia by providing human resource training support and medical-related education, and by contributing to the development of academic research. (Chairman: Seigo Kitano, President of Oita University)
For questions or additional information, please contact: Europe, Middle East and Africa (EMEA) Matthias Gengenbach +49 4023773 5867 matthias.gengenbach@olympus-europa.com
BitDeer.com, the world’s leading all-in-one mining service platform, is launching a series of promotional offers to ring in the celebration of the Year of the Bull for this year’s Spring Festival. Limited stocks of mining plans for the highly-sought after S19 mining machines will be available, alongside the mining plans for S17 and T17 models. Other coupons and other prizes are also on offer during the event.
With the fast-approaching Spring Festival of 2021 around the corner, the world’s leading all-in-one computing power service, BitDeer.com, is rolling out a promotional event to celebrate the festivities.
From February 3rd, 2021 to February 16th, 2021, there will be promotions and offers for the occasion. During the Spring Festival promotional period, BitDeer.com will offer short term mining plans with the duration of 90 days or 120 days for the Antminer S19, S17, and T17 series models. At present, the 90-day mining plan is the shortest mining period available on the platform. According to BitDeer.com, the shorter mining plan is suitable for those who prefer a higher degree of control. Since the short plan lapses before the start of the wet season, possible risks due to fluctuations are avoided. The S19 plans at BitDeer.com have always been a best-seller, with plans being frequently snapped up at a fast rate as soon as they are restocked. The platform has not only been able to secure supply of the in-demand S19 model, but also S17 and T17 series machines, giving its user base a variety of options.
Within the Spring Festival event, BitDeer.com users who log on into the web platform or their new mobile app version of their mining platform would have a chance to receive coupons, with the highest amount valued at $100. These freebies will only be available to customers who log in during the Spring Festival. Aside from this, purchasers of a certain amount in mining plans will receive complementary mining extension coupons which can cover mining days of up to 7 days, with hashrates free of charge. Mystery prizes are also up for grabs for users who greet BitDeer.com with Chinese New Year couplets. Newcomers to BitDeer.com will also be able to enjoy a special welcome package with coupons redeemable during the Spring Festival.
BitDeer.com regularly gives back to its community through promotional offers during special occasions, as well as keep up with the market conditions to provide sufficient supply of opportunities for potential gains. During the last 2 years since its debut, the all-in-one mining service platform has established itself as a reputable world leader in the industry for both individuals and institutions. BitDeer.com aims to continue providing services that are transparent, reliable, and adaptable to different needs and market conditions.
“BitDeer.com will be here to support our users throughout any climate”, a representative said.
For more information on BitDeer.com and its services, please visit the official website. https://www.BitDeer.com
About BitDeer.com BitDeer.com is the world’s leading all-in-one mining service platform, enabling global users to mine cryptocurrencies in a transparent, reliable, and convenient way. It saves users from the complicated process of purchasing, installing, and hosting mining machines. Individual and institutional investors can enjoy the service with just one click.
Recently, a famous Korean BBQ restaurant on Elizabeth Street in the CBD of Melbourne, Australia, took in a new member to deliver food in the store. That is PuduBot, the iconic delivery robot from Pudu Robotics.
PuduBot has been well received by the locals since its introduction in the restaurant. While waiting for the food to be served, many customers use their mobile phones to take photos or videos of PuduBot hustling and bustling around.
Robot waiters are nothing new in the modern world, but people may wonder “How does the robot deliver food to the designated location? How does it avoid people coming and going? Is it reliable? And how can it ensure the food is not spilled or dropped?”
Well, it’s all a piece of cake for PuduBot! PuduBot is developed by Pudu Robotics, a world-leading provider of commercial robots. The company is headquartered in Shenzhen, the global epicenter of hardware innovation, and has set up R&D centers in Shenzhen, Beijing and Chengdu, and hundreds of offices across the country. Pudu has developed over 400 patents, more than 60% of which are utility patents. Relying on the core technologies of low-speed autonomous driving, robotics motor, and motion control, Pudu has launched top-notch delivery and disinfection robots to the market.
As we know, Pudu’s delivery robot features automatic driving, positioning and navigation, and obstacle avoidance. So how does this work? It is made possible by the multi-sensor PUDU SLAM algorithm independently developed by Pudu. This cutting-edge technology integrates the data from the vision camera, lidar, RGBD camera, IMU, encoder, ultrasonic sensor and many more sensors, enabling centimeter-level map construction and positioning with high precision and robustness.
When performing a task, the robot first identifies its own position and direction, makes global path planning based on the map and destination, and follows the calculated optimal path.
During its movement, the robot processes data from sensors through the perception algorithm, accurately identifies obstacles in the environment, and generates a high-precision, multi-layer semantic map. It also makes local path planning to fine-tune the trajectory in real time while maintaining the general direction of the global path, allowing for flexible obstacle avoidance.
Furthermore, thanks to the auto-level independent linkage suspension pioneered by Pudu Robotics, PuduBot provides sound damping performance comparable to vehicles, ensuring stable delivery of food and drink even when an obstacle is standing in the way.
Most Pudu delivery robots come with a pleasingly simple appearance. Take PuduBot for example. Equipped with 3-4 trays, the body features a streamlined, lightweight design in colors of black and white, making it easier to blend into the environment. In the idle state, PuduBot presents cute and vivid expressions as appropriate on its navigation-sized screen.
Today, Pudu’s delivery robots have been sold all over the world. They have found wide applications in restaurants, hospitals, supermarkets, and even airports and office buildings of all sizes, providing flexible delivery that users can rely on.
HKVAX, an Asian startup focused on developing a compliant virtual asset exchange, has been nominated for KPMG’s “2020 China Leading Fintech 50”, alongside other notable fintech companies such as Futu, Ping An and CCB Fintech.
HKVAX is focused on developing a compliant trading environment for virtual assets and is expecting to be licensed in 2021 subject to regulatory approval. The approved licenses would allow HKVAX to legally operate a regulated virtual asset exchange and to deal in securities.
The platform will provide a curated venue for professionals and institutions to trade virtual assets and offer catered listing rules and guidance for virtual assets and security tokens. HKVAX also provides “24/7 Real-Time” transactions around the clock with market liquidity to allow trading operations to function efficiently and effectively.
HKVAX also has plans to launch their licensed institutional grade custodian solution in early Q2 of 2021. The TCSP license was received earlier in 2019 making HKVAX a fully licensed trust company and is compliant with the strictest AML, CTF, FATF and other global regulatory requirements. This allows HKVAX to provide the highest level of service and safeguard client assets in a fully regulated custodial environment.
For potential clients and parties interested in the technology powering HKVAX, the company has recently launched their testnet solution, “Sim-Trade HKVAX”, during Q4 2020 and invite users to test the trading environment.
About HKVAX HKVAX is a regulated virtual asset exchange in Hong Kong that is building a trusted and secured infrastructure layer for trading, where different parties can collaborate with each other, investors having exposure to the new digital asset class, and issuers can engage with a wide range of investors. Creating a safe, fair and bona fide environment for everyone. For more information on HKVAX and their initiatives, please visit the official website. https://www.hkvax.com
Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of a new comprehensive educational platform designed to provide healthcare professionals (HCPs) all over the world with learning opportunities and training to put their skills into practice and keep them performing at their best.
The “Olympus Continuum” (www.olympuscontinuum.com) platform will empower HCPs at every stage of their career with innovative, premium education and specialized training experiences. The platform builds on the existing Olympus training program, which trains more than 25,000 HCPs annually over 1,400 courses.
Chief Medical Officer, Ross D. Segan, MD, MBA, FACS, said: “Healthcare professionals work in a variety of settings and have a multitude of needs–and their expectations for training courses have evolved well past traditional skills-based learning. Our new platform connects the continuum of care with the continuum of learning. A truly blended experience, Olympus Continuum maximizes digital self-guided pre-learning, direct in-person training, and post-learning collaboration to support healthcare professional across every stage of their career and to improve patient outcome.”
HCPs using the “Olympus Continuum” platform will enjoy the following benefits:
– Comprehensive platform programs covering basic to advanced levels: The Olympus global professional education strategy is to establish a continuum of blended learning that takes HCPs from basic to advanced, providing more educational opportunities/experiences and increasing accessibility through the utilization of technology. Hands-on courses will be provided in our 15 dedicated Olympus training labs, as well as hospitals and other labs all over the world.
– Beneficial for remote areas, including emerging countries: In some emerging countries and hard-to-reach areas, it has been difficult for HCPs to receive training or enroll in educational programs because of limited course offerings and large geographical distances. “Olympus Continuum” is a globalized and comprehensive platform of training and education experiences led by healthcare experts from around the world.
– Effective platform that fits well with current conditions created by the COVID-19 pandemic: There was growing demand from healthcare professionals for on-demand, digitally-enabled virtual training and this has increased further during the current COVID-19 pandemic. This new platform exactly meets this demand and provides an excellent combination of virtual and on-site training.
Learning opportunities include hands-on courses, online learning, lectures and workshops, peer-to-peer training, accredited continuing education and on-demand learning.* To learn more about Olympus Continuum, visit www.olympuscontinuum.com
*Implementation will vary from region to region given market environments.
About Olympus Continuum
Olympus Continuum is a newly launched educational platform for healthcare professionals that will bring the benefits of digitally-enabled learning to remote regions, as well as those impacted by COVID-19. Basic and advanced training for healthcare professionals will be provided through Olympus training centers and hospitals all over the world.
About Olympus
Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries. Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit https://www.olympus-global.com/.
For questions or additional information, please contact: Europe, Middle East and Africa Matthias Gengenbach +49 4023773 5867 matthias.gengenbach@olympus-europa.com
Olympus Corporation (Olympus – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest – CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.
Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.
Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus’ existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks. The Quest technology acquired is intended to expand opportunities for Olympus in this field.
Making the Invisible Visible
Quest offers innovative technologies for multi-spectral imaging and imaging systems for medical applications, ranging from fluorescence imaging to photodynamic therapy. The acquisition strengthens Olympus’ position as a world leader in medical imaging solutions, and delivers innovative capabilities (including 3D and 4K imaging) to surgeons, to “make the invisible visible.”
Quest’s lead product line is the Quest Spectrum Fluorescence Imaging System, which enables fluorescence-guided surgery for open and minimally invasive procedures. Kanichi Matsumoto, global head of Surgical Endoscopy at Olympus, said: “We are delighted to incorporate Quest’s advanced FIS capabilities into our comprehensive medical imaging portfolio. The combination of the Quest Spectrum product line’s leading FIS technologies with Olympus’ existing laparoscopic imaging system VISERA ELITE II will enable Olympus to offer surgeons a wide range of high quality fluorescence imaging solutions.”
New Applications and Market Growth
The global market for FIS devices is expected to grow at a compounding annual rate of more than 12%, from around US$310 million in 2018 to over US$827 million in 2027*. Increasing demand for minimally invasive procedures and reconstructive surgery is helping to drive FIS growth worldwide. Furthermore, application of the FIS technology is expected to expand over the coming years, as additional fluorescent dyes are paired with targeted antibodies. Among other applications, molecular imaging will allow healthcare professionals to visualize cancerous lesions in vivo and perform cancer surgery in unprecedented ways, potentially lowering recurrence rates.
Quest also works with biotechnology companies that are developing next-generation molecular imaging dyes. These innovative dyes may enable Quest’s technology to advance diagnostic opportunities in fluorescence-guided cancer surgery.
*Source: Transparency Market Research; Near-Infrared Fluorescence Imaging System Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019-2027.
About Quest
Quest Photonic Devices B.V. is a multispectral imaging leader and focuses on the medical markets of fluorescence image-guided surgery and cancer-targeted probes. Quest’s next generation Spectrum Florescence Imaging System has the ability to “see through tissue” with enhanced sensitivity, capable of accessing otherwise inaccessible information to aid the surgeon in improving clinical outcomes.
About Olympus’ Medical business
As a leading medical technology company, Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
For questions or additional information, please contact:
Stock Up Express (www.stockupexpress.com) Receives More Than 1,000,000 Annual Online Visitors, Consisting of a Diverse Group of Customers
Tauriga Sciences, Inc. (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has entered into a distribution agreement (the “Agreement”) with Stock Up Express, a division of a leading total services distributor that generates more than $3 Billion in annual sales. Stock Up Express is based in Connecticut and is a leading web-based grocer and wholesaler with over 1,000,000 online visitors annually. The Agreement will be effective February 1, 2021, and shall remain in effect for a period of two (2) years thereafter, with automatic renewal for additional successive one (1) year terms.
Under terms of the Agreement, Stock Up Express will market and resell the Company’s flagship brand, Tauri-Gum(TM), to its large and diverse customer base of wholesalers and retail customers. The revenue sharing ratio established between Tauriga and Stock Up Express has the potential to create significant opportunity for both parties to this Agreement (solid gross margins). Tauri-Gum(TM) represents the first CBD edibles product/product line to be selected as part of the Stock Up Express network.
The two Companies will jointly market Tauri-Gum(TM) to Stock Up Express’ customer base, with input by Tauriga on the content of such marketing information to attain consistency on message and to maximize sales. The Agreement allows for modification of product offerings, and Tauriga expects to offer additional items over the course of calendar year 2021.
Tauriga’s CEO, Seth M. Shaw, expressed, “This agreement is an important achievement for Tauriga. Due to the quality of our flagship Tauri-Gum(TM) product line, the strong team that we have built, and the improving macro-outlook for our industry, this Agreement became possible. Stock Up Express is an outstanding distribution partner and the Company now has access to a large, previously untapped, market segment, at margins that the Company believes is conducive to long term success. Our long-term goal is for Tauri-Gum(TM) to become a successful, widely distributed, consumer friendly CBD edibles brand. We have now taken an important step in that direction.”
Stock Up Express’ Vice President of E-Commerce, Steven Methvin, commented, “After much consideration and the evaluation of numerous CBD products, our Company has made the decision to enter the CBD edibles space through Tauriga Sciences Inc. and its high-quality products. Stock Up Express will provide an opportunity to present the Tauri-Gum(TM) brand (and possibly other product offerings to follow) to a large and engaged base of wholesalers and retail customers. Our respective teams work well together and we are all committed to working hard and strategically to build a successful distribution partnership and business model.”
Tauriga Sciences, Inc. was represented by the law firm of Rimon P.C. in the preparation of the Agreement.
ABOUT TAURIGA SCIENCES, INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum(TM), consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum(TM) Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum(TM) Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum(TM), for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum(TM). The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.” On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.
On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.
ABOUT STOCK UP EXPRESS ONLINE Convenient Warehouse Shopping: We know you need to buy lots of goods with no time to waste. That’s why we created our virtual warehouse. At StockUpExpress, we sell case-size quantities of grocery, personal care, and household items from hundreds of national and regional brands. Since we are all about convenience, items in our cases are the normal shelf-size, not the jumbo club-size packaging offered at the big box stores. Unlike other e-commerce sites, StockUpExpress has the capability to ship mass amounts of product quickly and efficiently. We cover the heavy lifting and logistics, letting your business or event run smoothly all with just the click of a button. Development for Stock Up Express began in 2014. Our parent company, iMarket Technologies, LLC, was also launched in 2014 and is led by a team of executives with deep experience in warehouse operations, consumer packaged goods merchandising, logistics, and online retailing. Please visit our Website at: https://www.stockupexpress.com
DISCLAIMER — Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com Cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com
